FDA advisors say no to MDMA. What’s the impact? With Josh Hardman
Business Trip
00:00
Navigating Psychedelic Therapy's Future
This chapter examines the implications of recent FDA advisory decisions affecting MDMA's therapeutic approval and its impact on the psychedelic therapy market. It highlights concerns regarding finances for companies and clinics, discusses evolving clinical trial methodologies, and the intersection of psychotherapy with drug treatments. The conversation further addresses investor confidence, the shift towards non-hallucinogenic therapies, and the potential involvement of larger pharmaceutical companies in transforming mental health treatment.
Transcript
Play full episode
